论文部分内容阅读
小肠腺癌是较少见的恶性肿瘤，其发病与不健康饮食、基因突变和某些遗传性疾病有关，十二指肠是好发部位。小肠腺癌的5年生存率较低，临床多采用手术切除及术后辅助化疗的治疗方式。术后辅助化疗能改善无瘤生存期，但对总生存期无明显改善；对晚期癌症患者，使用FOLFOX方案（5-氟尿嘧啶、亚叶酸钙和奥沙利铂）疗效较好。血清中基础癌胚抗原和糖类抗原19-9水平是评估预后的主要因素，而分子靶向治疗尚处在探索中。“,”Small bowel adenocarcinomas ( SBA ) are relatively rare kinds of malignant tumours. Unhealthy diet,gene mutation and genetic diseases have been associated with increased risk of SBA .Duode-nal is the primary site of SBA.The 5-year survival rate of SBA patients is low.Radical resection and postoper-ative adjuvant chemotherapy is the general clinical treatment for SBA ,althoughf adjuvant chemotherapy after operation can improve the disease-free survival,but has no obvious effect on the overall survival.In patients with advanced cancer,FOLFOX scheme (fluorouracil,leucovorin and oxaliplatin) has better effect.The ser-um levels of carcinoembryonic antigen and carbohydrate antigen 19-9 are the only variables significantly asso-ciated with prognostic assessment.While molecular targeted therapy for SBA has been under exploration.